tumor burden

tu·mor bur·den

the total mass of tumor tissue carried by a patient with a malignancy.

tu·mor bur·den

(tū'mŏr bŭr'dĕn)
The total mass of tumor tissue carried by a patient with cancer.
Synonym(s): tumour burden.

tumor burden

The sum of cancer cells present in the body.
References in periodicals archive ?
Molecular imaging methods are capable of this while at the same time circumventing sampling error as the whole tumor burden is evaluated.
Successful treatment of cancer depends on understanding the heterogeneity of the patient's tumor burden and the driving genetic alterations behind disease progression," said Murali Prahalad, Ph.
They cross the blood-brain/blood-tumor barrier, and accumulate within brain tumor sites, where they target oncogenes, regulate cell growth and differentiation, reduce tumor burden and prolong survival in our mouse models.
In mouse xenograft models, in which human lung tumor cells are implanted in mice, treatment with the patented compound leads to dramatic reduction in tumor burden.
The EF-20 study builds on extensive preclinical research demonstrating the effectiveness of NovoTTF Therapy alone and in combination with gemcitabine in significantly decreasing tumor burden in animal and human cell pancreatic models," said Uri Weinberg, MD, PhD, Vice President, Research and Development of Novocure.
Similarly, in another mouse model of chemotherapy-resistant ovarian cancer, KPT-330 significantly reduced the tumor burden and improved overall survival when compared against the current gold-standard platinum treatment.
In phase I, biomarker kinetics and correlation with tumor burden are assessed.
It would be in the best interest of all involved due to the deleterious effects of malnutrition on compliance with oncologic therapies, the response to treatment and the growing experience, that early nutritional intervention when tumor burden is still limited is able to achieve a clinical benefit.
5) The tumor burden of extensive widespread metastases can essentially starve to death a patient with lung cancer.
Tumor incidence and multiplicity did not differ between the low dose-treated and the control groups, but the low dose treatment resulted in a substantial reduction of the overall tumor burden.
25 and 25 pg/L) significantly decreased tumor latency and increased tumor multiplicity, tumor burden, and the incidence of metastasis.